Abstract
Although most patients with postmenopausal osteoporosis have normal or low values for serum immunoreactive parathyroid hormone (iPTH), the authors have reported previously that a small subset (about 10% of the total group) have increased values. The authors studied three patients representative of this latter group. Serum iPTH was two to three times higher than the age-adjusted normal mean, serum ionized calcium and total calcium were in the lower half of the normal range, and serum 1,25-dihydroxyvitamin D [1,25(OH) 2D] was in the low-normal range. Six months of treatment of one patients with 0.5 μg/day of synthetic 1,25(OH) 2D improved calcium absorption and balance; however, serum iPTH remained high. After surgical removal of 1,010 mg of hyperplastic parathyroid tissue, serum iPTH decreased to normal. These and other data suggest that increased serum iPTH in these patients was caused by secondary hyperparathyroidism, possibly because of inadequate conversion of 25-OH-D to 1,25(OH) 2D.
| Original language | English |
|---|---|
| Pages (from-to) | 701-706 |
| Number of pages | 6 |
| Journal | Mayo Clinic Proceedings |
| Volume | 53 |
| Issue number | 11 |
| State | Published - 1978 |
| Externally published | Yes |
Fingerprint
All Science Journal Classification (ASJC) codes
- Medicine(all)
Cite this
A syndrome of osteoporosis, increased serum immunoreactive parathyroid hormone, and inappropriately low serum 1,25-dihydroxyvitamin D. / Riggs, B. L.; Gallagher, John Christopher G.; DeLuca, H. F.; Edis, A. J.; Lambert, P. W.; Arnaud, C. D.
In: Mayo Clinic Proceedings, Vol. 53, No. 11, 1978, p. 701-706.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - A syndrome of osteoporosis, increased serum immunoreactive parathyroid hormone, and inappropriately low serum 1,25-dihydroxyvitamin D
AU - Riggs, B. L.
AU - Gallagher, John Christopher G.
AU - DeLuca, H. F.
AU - Edis, A. J.
AU - Lambert, P. W.
AU - Arnaud, C. D.
PY - 1978
Y1 - 1978
N2 - Although most patients with postmenopausal osteoporosis have normal or low values for serum immunoreactive parathyroid hormone (iPTH), the authors have reported previously that a small subset (about 10% of the total group) have increased values. The authors studied three patients representative of this latter group. Serum iPTH was two to three times higher than the age-adjusted normal mean, serum ionized calcium and total calcium were in the lower half of the normal range, and serum 1,25-dihydroxyvitamin D [1,25(OH) 2D] was in the low-normal range. Six months of treatment of one patients with 0.5 μg/day of synthetic 1,25(OH) 2D improved calcium absorption and balance; however, serum iPTH remained high. After surgical removal of 1,010 mg of hyperplastic parathyroid tissue, serum iPTH decreased to normal. These and other data suggest that increased serum iPTH in these patients was caused by secondary hyperparathyroidism, possibly because of inadequate conversion of 25-OH-D to 1,25(OH) 2D.
AB - Although most patients with postmenopausal osteoporosis have normal or low values for serum immunoreactive parathyroid hormone (iPTH), the authors have reported previously that a small subset (about 10% of the total group) have increased values. The authors studied three patients representative of this latter group. Serum iPTH was two to three times higher than the age-adjusted normal mean, serum ionized calcium and total calcium were in the lower half of the normal range, and serum 1,25-dihydroxyvitamin D [1,25(OH) 2D] was in the low-normal range. Six months of treatment of one patients with 0.5 μg/day of synthetic 1,25(OH) 2D improved calcium absorption and balance; however, serum iPTH remained high. After surgical removal of 1,010 mg of hyperplastic parathyroid tissue, serum iPTH decreased to normal. These and other data suggest that increased serum iPTH in these patients was caused by secondary hyperparathyroidism, possibly because of inadequate conversion of 25-OH-D to 1,25(OH) 2D.
UR - http://www.scopus.com/inward/record.url?scp=0018126938&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0018126938&partnerID=8YFLogxK
M3 - Article
C2 - 713601
AN - SCOPUS:0018126938
VL - 53
SP - 701
EP - 706
JO - Mayo Clinic Proceedings
JF - Mayo Clinic Proceedings
SN - 0025-6196
IS - 11
ER -